CSPC DOPHEN CORP has a total of 11 patent applications. Its first patent ever was published in 2015. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets biotechnology, pharmaceuticals and foods and drinks are ALETA BIOTHERAPEUTICS INC, NACIONAL DE BIOPREPARADOS CENT and BLUEFIN BIOMEDICINE INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 4 | |
#2 | WIPO (World Intellectual Property Organization) | 2 | |
#3 | Australia | 1 | |
#4 | Canada | 1 | |
#5 | EPO (European Patent Office) | 1 | |
#6 | Japan | 1 | |
#7 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Foods and drinks | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Enzymes | |
#5 | Therapeutic chemical compounds | |
#6 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Hu Sean | 9 |
#2 | Allen Lisha | 9 |
#3 | Feng Lixin | 2 |
#4 | Browde Ryan Joseph | 1 |
#5 | Li Yingui | 1 |
#6 | Shan Yuxi | 1 |
#7 | Yan Zhe | 1 |
#8 | Lisha Allen | 1 |
#9 | Yang Ru Bin | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020257525A1 | Modified il-2 proteins, peg conjugates, and uses thereof | |
WO2020191092A1 | Anti-trophoblast cell surface antigen 2 (trop2) antibodies and antibody drug conjugates comprising same | |
KR20170031127A | Homogeneous antibody drug conjugates via enzymatic methods |